Cortechs.ai, a global innovator in AI-driven medical imaging, has achieved a pivotal regulatory milestone with the approval of its imaging software suite by Health Canada. This landmark decision allows Cortechs.ai to sell its diagnostic imaging tools in the Canadian healthcare market, empowering clinicians with state-of-the-art technology designed to enhance patient diagnosis and streamline radiology workflows.

Highlights of the Approval and Its Impacts:

1. Expansion into the Canadian Healthcare Market:

• Health Canada’s approval paves the way for Cortechs.ai to expand its global footprint.

• Canadian healthcare providers now have access to advanced AI solutions that support precision diagnostics and efficient care delivery.

• Strengthens the company’s international presence and credibility in regulated markets.

2. Overview of Cortechs.ai’s AI Imaging Solutions:

• NeuroQuant®: Offers automated segmentation and volumetric analysis of brain MRIs, supporting diagnosis and tracking of neurodegenerative diseases like Alzheimer's.

• NeuroQuant® MS: Tailored for Multiple Sclerosis monitoring, providing critical insights for disease progression and management.

• NeuroQuant® Brain Tumor: Quantitative MR imaging analysis to assist radiologists in brain tumor evaluation with higher accuracy.

• OnQ™ Prostate: Enhances interpretation of prostate MRIs, aiding in more accurate prostate cancer assessment and planning.

3. Benefits to Clinicians and Healthcare Institutions:

• Reduces time spent on manual image analysis.

• Delivers consistent, data-driven insights to improve diagnostic confidence.

• Supports early detection and long-term disease monitoring.

• Streamlines workflows, especially in high-volume radiology environments.

4. Cortechs.ai’s Vision and Mission Reinforced:

• The company reaffirms its goal to revolutionize medical diagnostics globally using AI.

• By expanding into Canada, Cortechs.ai continues to bridge technology and healthcare to improve outcomes.

• VP Jared Dixon highlighted the approval as “a monumental achievement” in advancing patient care with AI solutions.

Cortechs.ai’s Health Canada approval marks more than just regulatory success—it signals a transformative moment for Canadian healthcare. By introducing AI-enhanced imaging solutions like NeuroQuant and OnQ™ Prostate, Cortechs.ai empowers clinicians with powerful tools to elevate diagnostic accuracy and patient care. As the company strengthens its global reach, it stays true to its mission: to revolutionize disease detection and treatment through the power of AI.